DCTH Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (1 Jul 2024 @ 16:00):
Our systems believe the stock currently is undervalued by 0.17% compare to its pairs and should correct upwards.

Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe...

Stats
Today's Volume	151 686
Average Volume	273 330
Market Cap	229.51M
EPS	$-0.450 ( Q1 \| 2024-05-14 )
Next earnings date	( $-0.340 ) 2024-08-14
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-3.15 (Sector) 42.63 (Industry) 0
ATR14	$0.0140 (0.17%)

AEMD -9.77%

AFIB -12.68%

AHCO -2.70%

AHPI 0.00%

ALGN -1.16%

ANIK 2.05%

APEN 0.00%

APYX -2.99%

ARAY -3.30%

ATEC -4.50%

AXDX 0.00%

AXGN 6.49%

AXNX 0.10%

AZYO 2.05%

BBLG -2.44%

BIOL 7.80%

BJDX 0.87%

BMRA 0.07%

BRKR -2.32%

BSGM -0.06%

BWAY -3.46%

CERS -2.27%

CFMS 0.44%

CLPT -1.11%

CODX 0.80%

CSII 0.15%

CTKB 0.54%

CTSO -0.43%

CUTR -0.66%

CVRX -2.34%

DCTH -1.31%

DXCM -1.07%

DYNT -16.23%

EAR -4.10%

ECOR 0.00%

EDAP -4.04%

ESTA -4.62%

FONR 0.88%

HJLI -1.98%

HSDT -1.15%

HSKA 0.00%

HYPR 8.07%

IART -0.58%

ICAD -2.69%

ICCM -0.68%

IINN -11.59%

INGN -3.69%

INMD -2.03%

IRIX -3.24%

IRMD -1.14%

IRTC -1.11%

ISO 0.00%

ITMR 0.00%

KIDS -1.91%

LHDX 0.00%

LIVN -0.62%

LNSR -1.22%

LUCD -3.78%

LUNG -1.58%

MASS -7.38%

MDGS 10.28%

MOTS -16.81%

MOVE 5.78%

MSON 0.00%

NAOV -0.10%

NARI 4.24%

NMRD 33.33%

NNOX -2.59%

NPCE -3.17%

NTUS 0.00%

NURO -1.62%

NUVA -2.24%

NUWE -3.18%

NVCN 0.00%

NVNO -2.48%

OBLN -5.86%

OFIX -2.87%

OM -4.16%

PACB -12.41%

PAVM -6.26%

PETV -23.08%

PODD -2.79%

PRCT 1.28%

PROF 2.01%

QIPT -1.24%

QTRX -4.01%

RCEL -2.53%

RPID 3.05%

RSLS 3.86%

RWLK 6.07%

RXST -5.60%

SGHT -5.40%

SIBN -0.23%

SIEN -18.69%

SILK -0.33%

SINT -5.21%

SOLY 0.00%

SRDX -0.33%

SRGA 0.00%

SRTS -6.47%

SWAV 0.00%

TBIO 5.75%

TCMD -4.44%

TELA -4.47%

THMO -16.67%

TIVC -1.19%

TLIS -4.20%

TMCI -2.41%

TMDI 0.00%

TMDX -0.29%

TNDM -2.08%

TNON 18.05%

UFPT 9.56%

VERO -8.17%

VIVE 0.00%

VMD -2.29%

VRAY 0.00%

VREX -2.99%

VVOS 6.31%

XAIR 18.39%

XENT 0.00%

ZIMV -0.66%

Insider Trading

Date	Person	Action	Amount	type
2024-05-23	Czerepak Elizabeth	Buy	22 500	Stock Option (right to buy)
2024-05-23	Sylvester John Richard	Buy	22 500	Stock Option (right to buy)
2024-05-23	Salamon Steven A J	Buy	22 500	Stock Option (right to buy)
2024-05-23	Aharon Gil	Buy	22 500	Stock Option (right to buy)
2024-05-23	Martell Bridget A	Buy	22 500	Stock Option (right to buy)

INSIDER POWER
96.43
Last 97 transactions
Buy: 15 012 266 \| Sell: 485 932

Correlation (AI algo v.1.1b): Undervalued: 0.17% $8.27 paired level. (The Algo Track The Changes Of The Most Correlated Stocks In Realtime And Give An Instant Update)

Volume Correlation

Long: -0.02 (neutral)

Short: -0.50 (weak negative)

Signal:(43.54) Neutral

Delcath Systems Inc Correlation

10 Most Positive Correlations
OZEM	1
MSSA	0.905
REFR	0.903
IZEA	0.901
WLFC	0.901
WHLRD	0.899
LSAK	0.895
UEIC	0.887
GOOGL	0.882
GOOG	0.88

10 Most Negative Correlations
PYCR	-0.899
LINK	-0.889
TMCI	-0.888
GLYC	-0.885
ARAY	-0.885
SPT	-0.882
HOLI	-0.876
ASNS	-0.873
MRAM	-0.872
ISSC	-0.87

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Delcath Systems Inc Correlation - Currency/Commodity

-0.27
( neutral )

-0.02
( neutral )

0.00
( neutral )

-0.17
( neutral )

0.16
( neutral )

-0.17
( neutral )

Delcath Systems Inc Financials

Annual	2023
Revenue:	$2.07M
Gross Profit:	$1.30M (63.05 %)
EPS:	$-2.94

FY	2023
Revenue:	$2.07M
Gross Profit:	$1.30M (63.05 %)
EPS:	$-2.94

FY	2022
Revenue:	$2.72M
Gross Profit:	$2.03M (74.77 %)
EPS:	$-4.42

FY	2021
Revenue:	$3.56M
Gross Profit:	$2.88M (81.13 %)
EPS:	$-8.85

Financial Reports:

No articles found.

Delcath Systems Inc Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Delcath Systems Inc

Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan hydrochloride for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with hepatic dominant ocular melanoma to investigate objective response rate in metastatic ocular melanoma. The company also provides HEPZATO as a stand-alone medical device for sale under the CHEMOSAT Hepatic Delivery System for Melphalan trade name for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.